



The Role of Microorganisms in the Development of Biological Drugs

Guest Editors:

Dr. Jingyu Chen

College of Food Science &
Nutritional Engineering, China
Agricultural University, Beijing
100083, China

Dr. Annett Mikolasch

Institute for Microbiology,
University of Greifswald,
Greifswald, Germany

Dr. Mariam Gaid

Technische Universität
Braunschweig, 38106
Braunschweig, Germany

Deadline for manuscript
submissions:

closed (15 December 2023)

Message from the Guest Editors

Recent developments in the understanding of the human microbiome provided evidence of the therapeutic potential of selected micro-organisms to prevent or treat disease. In recent years, the concept of "next-generation probiotics" has been proposed, with new drugs and micro-organisms being considered as "live biotherapeutic products (LBP)". According to the FDA's definition, which was published in 2016, LBP are living bacterial drugs that can be used to prevent or treat certain human diseases and symptoms. Due to these clear advantages, LBP have been the subject of various recent drug development research projects and have broad development prospects.

This Special Issue will provide insights into novel drugs' promising biosynthesis and biotransformation strategies, as well as recent development of novel LBPs. Moreover, the latest proven enzyme-mediated routes, which use single-step biotransformation or enzyme cascade synthesis to achieve optimal outcomes, will be discussed.





an Open Access Journal by MDPI

Editor-in-Chief

Dr. Nico Jehmlich

Department of Molecular
Systems Biology, UFZ-Helmholtz
Centre for Environmental
Research, 04318 Leipzig,
Germany

Message from the Editor-in-Chief

"Microorganism" merges the idea of the very small with the idea of the evolving reproducing organism is a unifying principle for the discipline of microbiology. Our journal recognizes the broadly diverse yet connected nature of microorganisms and provides an advanced publishing forum for original articles from scientists involved in high-quality basic and applied research on any prokaryotic or eukaryotic microorganism, and for research on the ecology, genomics and evolution of microbial communities as well as that exploring cultured microorganisms in the laboratory.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, PubAg, CAPlus / SciFinder, AGRIS, and other databases.

Journal Rank: JCR - Q2 (*Microbiology*) / CiteScore - Q2 (*Microbiology (medical)*)

Contact Us

Microorganisms Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/microorganisms
microorganisms@mdpi.com
X@Micro_MDPI